The Defense Advanced Research Projects Agency (DARPA) is offering this grant under its Autonomous Diagnostics to Enable Prevention and Therapeutics (ADEPT) program. This grant is for the development of innovative nucleic acid platforms. The primary objective is to create systems capable of achieving in vivo host production of a transient immune prophylaxis specifically for adults. This prophylactic approach aims to enhance the body’s defense mechanisms against various environmental and contagious threats. Successful proposals will contribute to advanced prevention and therapeutic strategies by focusing on novel technologies that enable rapid and temporary immune protection within the host.
Opportunity ID: 205433
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | DARPA-13-03 |
| Funding Opportunity Title: | Autonomous Diagnostics to Enable Prevention and Therapeutics: Prophylactic Options to Environmental and Contagious Threats (ADEPT-PROTECT) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement Grant Other Procurement Contract |
| Category of Funding Activity: | Science and Technology and other Research and Development |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 12.910 — Research and Technology Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 2 |
| Posted Date: | Nov 01, 2012 |
| Last Updated Date: | Nov 21, 2012 |
| Original Closing Date for Applications: | Jan 15, 2013 |
| Current Closing Date for Applications: | Jan 15, 2013 |
| Archive Date: | Mar 15, 2013 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility” |
| Additional Information on Eligibility: | – |
Additional Information
| Agency Name: | DARPA – Defense Sciences Office |
| Description: | DARPA is soliciting proposals for the development of nucleic acid platforms capable of in vivo host production of a transient immune prophylaxis for adults as a component of the Autonomous Diagnostics to Enable Prevention and Therapeutics (ADEPT) program.See attached DARPA-BAA-13-03. |
| Link to Additional Information: | DARPA-BAA-13-03 |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
DARPA BAA Coordinator
Email:DARPA-BAA-13-03@darpa.mil |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
| The purpose of this Modification 1 to DARPA-BAA-13-03, Autonomous Diagnostics to Enable Prevention and Therapeutics: Prophylactic Options to Environmental and Contagious Threats (ADEPT-PROTECT) is to make the following change to the announcement: The following section is revised as follows: IV.B.5.a. Section II. Summary of Proposal g. A single PowerPoint slide summarizing the program and effort; use the template provided as an attachment to the announcement. |
Nov 21, 2012 | |
| Nov 21, 2012 |
DISPLAYING: Synopsis 2
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | DARPA-13-03 |
| Funding Opportunity Title: | Autonomous Diagnostics to Enable Prevention and Therapeutics: Prophylactic Options to Environmental and Contagious Threats (ADEPT-PROTECT) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement Grant Other Procurement Contract |
| Category of Funding Activity: | Science and Technology and other Research and Development |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 12.910 — Research and Technology Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 2 |
| Posted Date: | Nov 01, 2012 |
| Last Updated Date: | Nov 21, 2012 |
| Original Closing Date for Applications: | Jan 15, 2013 |
| Current Closing Date for Applications: | Jan 15, 2013 |
| Archive Date: | Mar 15, 2013 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility” |
| Additional Information on Eligibility: | – |
Additional Information
| Agency Name: | DARPA – Defense Sciences Office |
| Description: | DARPA is soliciting proposals for the development of nucleic acid platforms capable of in vivo host production of a transient immune prophylaxis for adults as a component of the Autonomous Diagnostics to Enable Prevention and Therapeutics (ADEPT) program.See attached DARPA-BAA-13-03. |
| Link to Additional Information: | DARPA-BAA-13-03 |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
DARPA BAA Coordinator
Email:DARPA-BAA-13-03@darpa.mil |
DISPLAYING: Synopsis 1
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | DARPA-13-03 |
| Funding Opportunity Title: | Autonomous Diagnostics to Enable Prevention and Therapeutics: Prophylactic Options to Environmental and Contagious Threats (ADEPT-PROTECT) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement Grant Other Procurement Contract |
| Category of Funding Activity: | Science and Technology and other Research and Development |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 12.910 — Research and Technology Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Nov 21, 2012 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | – |
| Current Closing Date for Applications: | Jan 15, 2013 |
| Archive Date: | Mar 15, 2013 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility” |
| Additional Information on Eligibility: | – |
Additional Information
| Agency Name: | DARPA – Defense Sciences Office |
| Description: | DARPA is soliciting proposals for the development of nucleic acid platforms capable of in vivo host production of a transient immune prophylaxis for adults as a component of the Autonomous Diagnostics to Enable Prevention and Therapeutics (ADEPT) program.
See attached DARPA-BAA-13-03. |
| Link to Additional Information: | DARPA-BAA-13-03 |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
DARPA BAA Coordinator
Email:DARPA-BAA-13-03@darpa.mil |
Related Documents
Folder 205433 Full Announcement-1 -> darpa-baa-13-03.pdf
Folder 205433 Full Announcement-2 -> penta chart template.pdf
Folder 205433 Full Announcement-2 -> darpa-baa-13-03 modification 1.pdf
Packages
| Agency Contact Information: | DARPA BAA Coordinator Email: DARPA-BAA-13-03@darpa.mil |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| 12.910 | PKG00150850 | Nov 01, 2012 | Jan 15, 2013 | View |
Package 1
Mandatory forms
205433 RR_SF424-1.1.pdf
Optional forms
205433 RR_FedNonFedBudget-1.1.pdf
205433 RR_FedNonFed_SubawardBudget-1.2.pdf
205433 RR_OtherProjectInfo-1.1.pdf
205433 RR_Budget-1.1.pdf
205433 RR_KeyPersonExpanded-1.1.pdf
205433 RR_PerformanceSite-1.1.pdf
205433 RR_SubawardBudget-1.2.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
